电脑桌面
添加小米粒文库到电脑桌面
安装后可以在桌面快捷访问

维持治疗的分子靶标作用VIP免费

维持治疗的分子靶标作用_第1页
1/29
维持治疗的分子靶标作用_第2页
2/29
维持治疗的分子靶标作用_第3页
3/29
PhilipC.Mack,PhDAssociateAdjunctProfessorUCDavisCancerCenterHowdoweperformmoreeffectivebiomarkertestingformatchingNSCLCpatientswithoptimaltherapyformaintenanceofdiseaseremissionandafterrelapsedNSCLC?Apatienthasbenefitedfromtreatment(tumorresponseordurablestabledisease)Howcanweusebiomarkerstohelp:1)Maintainarespondingpatientinadiseasecontrolstate?2)Restorearelapsingpatienttoadiseasecontrolstate?Whatbiologicinformationisavailable?BaselinespecimensAcquiredpriortopreviousinterventionsDiagnosticFFPEspecimen?Biomarkerinfoobtained?Baselineblooddraw?Post-progressionspecimensAcquireduponprogressionfollowingmeaningfulbenefitSecondbiopsy?Serialblooddraws?ErlotinibPemetrexedBevacizumabDocetaxelGemcitabineMaintenanceTherapyOptionsMaintenanceTherapyOptionsandAssociatedBiomarkersErlotinib–EGFRmutationspredictresponseEvidence:High,wellaccepted,standard-of-carePemetrexed–HighTSpredictresistanceEvidence:Strong,requiresadditionalvalidationoverhistologyBevacizumab–NoacceptedmarkersforbenefitConjecture:Possibilityofmarkersofacquiredresistance?Docetaxel–BetatubulinIIImutations/expressionlevelsEvidence:Weak,requiresextensivefurtherinvestigationGemcitabine–HighRRM1levelspredictresistanceEvidence:IntriguingbutcontroversialBiomarkerstrategiesfor“Continuous”maintenancetherapyi.e.pemetrexedmaintenanceinplatinum+pem-treatedpatientwithCR,PRorSDNobiomarkerscurrentlyapplicableBiomarkersshouldbeusedtoaidfront-linedecision-makingSuccessoffront-linetherapyischiefindicatorforutilityofcontinuousmaintenancestrategiesCurrentresearcheffortsfocusedonidentificationofemergentresistancemarkersBiomarkerstrategiesfor“Switch”maintenancetherapyi.e.erlotinibmaintenanceincarbo/pac-treatedpatientwithCR,PRorSDEstablishedbiomarkerswillberelevantBiomarkerspredictiveofbenefitfromanagentwouldbeexpectedtobeofutilityformaintenanceoptionsNote:ClinicalevidenceandgeneralconsensusamongexpertsisthatpatientsshouldreceiveFRONT-LINEtreatmentof:erlotinibforEGFRmutanttumorscrizotinibforEML4-ALKpositivetumors56-year-oldCaucasianfemale,never-smoker,presentswithcoughAbnormalCXR&CTscan:RULmass,multiplenodules,liverandbonymetastases.FNAofRULmass:adenocarcinoma,TTF1+KPS=90%;MRIbrain:negativeformetsCaseExample:56FNeversmokerPatientreceives4cyclesofcarboplatin/paclitaxelplusbevacizumab.RECISTBestResponse:partialresponseCoughresolved,otherwiseasymptomaticafter4cyclesCaseExample:56FNeversmokerCaseExample:56FNeversmoker2ndlineMaintenanceYourpathologistdeterminesthatthereissufficienttumormaterialformoleculartesting:TumorisfoundtobeEGFR-mutation-positive(Exon19deletion).Atthispointdoyou:34%38%24%4%A.“watchandwait”withCTscansevery2-3months,thenuseerlotinibatprogressionB.Continuewithbevacizumabuntilprogression,thenuseerlotinibC.StopbevacizumabandswitchtoerlotinibmaintenancetherapyD.Continuebevacizumab,adderlotinibformaintenancetherapySATURN:phaseIII,placebo-controlledtrialofmaintenanceerlotinib-EGFRmutationstatusIntention-to-treatpopulationEGFRmutant-positivepopulationThissubgroupbyfarshowedthemostbenefitSATURNTrialfindingsTheSATURNtrialshowedthaterlotinib,givenasmaintenanceimmediatelyafterastandardfirst-lineplatinum-basedchemotherapy,significantlyimprovedtheoutcomeofmNSCLCSignificantlyimprovedPFSwasnotedintheentireintent-to-treatpopulation,includi...

1、当您付费下载文档后,您只拥有了使用权限,并不意味着购买了版权,文档只能用于自身使用,不得用于其他商业用途(如 [转卖]进行直接盈利或[编辑后售卖]进行间接盈利)。
2、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。
3、如文档内容存在违规,或者侵犯商业秘密、侵犯著作权等,请点击“违规举报”。

碎片内容

维持治疗的分子靶标作用

确认删除?
VIP
微信客服
  • 扫码咨询
会员Q群
  • 会员专属群点击这里加入QQ群
客服邮箱
回到顶部